It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Breaking news: UK Supreme Court decision on pemetrexed – Eli Lilly’s patent held to be directly and indirectly infringed
-
Standard Essential Patents, Global Licensing Approach and the Principle of Territoriality
-
The CJEU decides that punitive damages are not contrary to Directive 2004/48
-
Ratification by Belgium of the UPC agreement
-
Lack of Clarity of Granted Claims in EPO Opposition Proceedings
-
Brazil and China in different directions?
-
More on G 0002/21: has the Robin Redbreast been freed from its cage?
-
Basics of the Unitary Patent system. Part 8: saisie and provisional measures
-
Added matter, Amendments, Case Law, Infringement, Litigation, Patents, Pharma, Pharmaceutical patent, Plausibility, Revocation, Sufficiency of disclosure, United Kingdom, Validity
Gilead Sciences v NuCana – two trials for the price of one (or two)
-
Amended Guidelines on Independence of the Swiss Federal Patent Court became effective on 1 January 2015 – An inspiring model for the UPC?